Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer

Pediatrics

Volumn 127, Issue 2, 2011, Pages

  Teuffel, Oliver ^a   Amir, Eitan ^b   Alibhai, Shabbir M H ^c,d   Beyene, Joseph ^a,d   Sung, Lillian ^a,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ambulatory care; Cost effectiveness; Fever; Neutropenia; Outpatient

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; CHILD; CLINICAL DECISION MAKING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; FEBRILE NEUTROPENIA; HEALTH CARE COST; HOME CARE; HUMAN; LOW RISK PATIENT; MODEL; OUTPATIENT CARE; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW;

AMBULATORY CARE; CHILD; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE MANAGEMENT; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 79551554214     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0734     Document Type: Article

References (35)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-751
2. Ammann RA, Hirt A, Lüthy AR, Aebi C. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003;41(5):436-443
3. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18(5):1012-1019
4. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28(10):665-670
5. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19(14):3415- 3421
6. Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol. 2009;31(9):635-641
7. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86(1):126-134
8. Paganini H, Gómez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003;97(7):1775-1780
9. Paganini HR, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer. 2000;88(12):2848-2852
10. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34(2):87-91 (Pubitemid 30090470)
11. Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22(18):3784-3789
12. Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm JC; United Kingdom Children's Cancer Study Group. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Arch Dis Child. 2007;92(6):495-498
13. Chamberlain JD, Smibert E, Skeen J, Alvaro F. Prospective audit of treatment of paediatric febrile neutropenia in Australasia. J Paediatr Child Health. 2005;41(11):598-603
14. Boragina M, Patel H, Reiter S, Dougherty G. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey. Pediatr Blood Cancer. 2007;48(5):521-526
15. Paulus S, Dobson S. Febrile neutropenia in children with cancer. Adv Exp Med Biol. 2009;634:185-204
16. Sung L, Feldman BM, Schwamborn G, et al. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences. J Clin Oncol. 2004;22(19):3922-3929
17. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381-396
18. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Costeffectiveness in Health and Medicine. JAMA. 1996;276(16):1339-1341
19. Teuffel O, Ethier MC, Alibhai SMH, et al. Outpatient Management of cancer patients with febrile neutropenia: a systematic review of meta-analysis. Ann Oncol. In press.
20. Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatr Blood Cancer. 2007;49(6):786-792 (Pubitemid 47519513)
21. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10(6):589-597
22. Simon A, Ammann RA, Bode U, et al. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis. 2008;8:70
23. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol. 2000;21(9):592-596
24. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593-603
25. VonNeumann J, Morgenstern O. Theory of Games and Economic Behaviour. 3rd ed. New York, NY: Princeton; 1953
26. Drummond MF, Sculpher MJ, Torrance JW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005
27. Patrick DL, Bush JW, Chen MM. Methods for measuring levels of well-being for a health status index. Health Serv Res. 1973;8(3):228-245
28. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21(4):329-334
29. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci. 1976;10(3):129-136
30. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422-437
31. Ungar WJ. Economic Evaluation in Child Health. New York, NY: Oxford University Press; 2010
32. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics. 2006;24(11):1121-1131
33. Bala MV, Zarkin GA. Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ. 2000;9(2):177-180
34. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying lowrisk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051
35. Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA. Medical and nonmedical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatr Blood Cancer. 2007;48(3):273-277 (Pubitemid 46238516)